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Abstract
Background: Major depressive disorders (MDD) is a common mental disorder with high prevalence, frequent
relapse and associated with heavy disease burden. Heritability, environment and their interaction play important
roles in the development of MDD. MDD patients usually display a wide variation in clinical symptoms and signs,
while the diagnosis of MDD is relatively subjective. The treatment response varies substantially between different
subtypes of MDD patients and only half respond adequately to the first antidepressant. This study aims to define
subtypes of MDD, develop multi-dimension diagnostic test and combined predictors for improving the diagnostic
accuracy and promoting personalized intervention in MDD patients.
Methods/Design: This is a multi-center, multi-stage and prospective study. The first stage of this study is a
case–control study, aims to explore the risk factors for developing MDD and then define the subtypes of MDD
using 1200 MDD patients and 1200 healthy controls with a set of questionnaire. The second stage is a diagnostic
test, aims to indentify and replicate the potential indicators to assist MDD diagnosis using 600 MDD patients and
300 healthy controls from the first stage with a set of questionnaire, neuropsychological assessment and a series of
biomarkers. The third stage is a 96-week longitudinal study, including 8-week acute period treatment and 88-week
stable period treatment, aims to identify overall predictors of treatment effectiveness on MDD at week 8 post
treatment and to explore the predictors on MDD prognosis in the following 2 years using 600 MDD patients from
the first stage with a set of questionnaire, neuropsychological assessment and a series of biomarkers. The primary
outcome measure is the change of the total score of 17-Item Hamilton Rating Scale for Depression.
Discussion: This study will provide strong and suitable evidence for enhancing the accuracy of MDD diagnosis and
promoting personalized treatment for MDD patients in clinical practice.
Trial registration: ClinicalTrials.gov: NCT02023567; registration date: December 2013.
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Background
Major depressive disorders (MDD) is a common, com-
plex, often difficult-to-treat and high-relapse clinical
condition [1]. MDD causes the largest amount of disabil-
ity, accounting for almost 12 % of all total years lived
with disability worldwide [2]. MDD was also a contribu-
tor of burden allocated to suicide and ischemic heart
disease [3]. The pain and suffering of individuals with
MDD and those close to them result in a heavy eco-
nomic toll to this country in terms of both treatment
costs and lost productivity [4]. China is also confronted
with this daunting challenges against MDD. It was
assessed that the 1-month prevalence of mood disorders
(mainly MDD) was 6.1 % [5].
MDD commonly arises when a vulnerable individual
confronts adversity. MDD is familial, with heritability es-
timated to be 0.37. Environmental influences specific to
an individual are also etiologically significant [6, 7]. Gen-
etic factors partially influence overall risk of illness, but
also influence the sensitivity of individuals to the
depression-inducing effects of environmental adversity.
The interaction of genotype and environment is signifi-
cant in the prediction of onset of MDD [8]. Despite de-
cades of research, there remains little consensus on how
to distinguish between MDD subtypes. Loo et al. exam-
ined the evidence for the existence of data-driven symp-
tomatic subtypes of depression and did not provide
conclusive evidence for the existence of depressive
symptom dimensions or symptomatic subtypes [9]. A
persistent theme in the debate on the classification of
MDD has been the question of how to distinguish bio-
logical depressions from depressions that are social in
origin. It appears to be “ at least partly” to distinguish
those individuals whose depressive illness is largely “gen-
etic” versus “environmental” [10]. One the other side,
some distinct subtypes had been suggested and found
subtypes associated with treatment outcomes [11–13].
For optimized treatment, it is probably meaningful to
classify MDD into different subtypes basing on its
psychopathology.
The diagnosis of MDD is based on relatively subjective
interviews and questionnaires for assessments of symp-
toms. However, affected individuals display quite a wide
variation in clinical symptoms and signs [10]. Even in
some high-income countries, people who are depressed
are not always correctly diagnosed [1]. Biomarkers in
psychiatry present a promising addition to advance the
diagnosis, treatment and prevention of psychiatric dis-
eases [14]. The development of reliable diagnostic tests
using biomarkers could aid in the diagnosis of MDD.
Many peripheral biomarkers, including inflammatory cy-
tokines, immunological markers, growth factors, endo-
crine factors, metabolic markers and oxidative stress
markers, have been investigated because these markers
are thought to be involved in the pathophysiology of
MDD [14–18]. However, it is clear that even though a
large number of biomarkers have been linked to MDD,
each individually explains a very modest proportion of
the variance in MDD risk. For clinical diagnosis of
MDD, all individual marker-based approaches yielded
insufficient sensitivity and specificity [19]. It had been
reported that a composite, multi-assay diagnostic test for
MDD demonstrated adequate sensitivity and specificity
(about 91 and 81 %) for American [19]. The results in a
Japanese population were not in conformity with those
in American [20]. It is needed to confirm the perform-
ance of the test in large Chinese sample.
Several treatments for MDD are available, while re-
sponse to treatments varies substantially between pa-
tients and more than half will fail to respond
adequately to the first antidepressant they are pre-
scribed [21]. The heterogeneity of treatment effects
complicates clinical decision-making. One approach to
enhancing treatment outcomes in MDD has been the
use of standardized sequential treatment algorithms
and measurement-based care. Pretreatment tests that
predict which patients will respond to which types of
treatment could save time, money and patient burden.
A large body of literature reported that some demo-
graphic characteristics, clinical symptoms, stress
events, genotypes and biomarkers could foretell overall
treatment outcome [11–13, 15, 22–37]. However, ro-
bust and combined predictors of treatment response
remain elusive [7, 38]. It is urgent and critical to com-
bine possible factors to form the basis of new para-
digms for antidepressant treatment selection.
Objectives
This study is designed to verify the role of heritability
and environment in the onset of MDD, define the sub-
types of MDD and evaluate a range of factors/predictors
to aid MDD diagnosis and personalized treatment within
MDD patients and healthy controls. The aims of this
study are to:
1. Verify the role of heritability and environment in the
onset of MDD and define the subtypes of MDD
according to the influence of heritability and
environment on its development.
2. Identify potential indicators to assist MDD diagnosis
basing on the baseline information,
neuropsychological assessment and biological
markers.
3. Identify overall predictors for treatment effectiveness
of selective serotonin reuptake inhibitors (SSRIs) on
MDD after up to 8 weeks
4. Explore the predictors on MDD prognosis in the
following two years.
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Methods/Design
Organizational structure and quality control
The infrastructure of this study includes an executive
management team, 9 clinical sites at 9 top tertiary hospi-
tals (7 within academic settings and 2 in clinical prac-
tices) located in 6 provinces/municipalities and one
clinical research organization. Each clinical site has a
principal investigator (responsible for all work in this
site), one research coordinator (responsible for the co-
ordination in this site/with the executive management
team), 2 to 4 investigators (responsible for recruitment,
clinical evaluation, neuropsychological assessment, blood
specimen collection), one data typist (responsible for en-
tering paper-based questionnaire data into a web-based
data system) and one clinical research assistant (CRA)
assigned by the clinical research organization (respon-
sible for supervising compliance to study protocol and
checking the conformance of the paper-based question-
naire and the web-based).
Each clinical sites are selected based on the likelihood
of executing the protocol and their previous research
experience. All principal investigators have chaired or
participated in some clinical studies. Prior to enrolling
participants in each site, work manuals will be supplied
to each site to provide instructions on all relevant re-
search issues, including enrollment, clinical evaluation,
neuropsychological assessment, serious adverse events
reporting procedure, data entering and checking and
blood specimen collection, storage and transportation.
The researchers are all strictly trained according to the
work manual. As a new staff joins in, they will be
trained by their principal investigator and research co-
ordinator. Clinical data are acquired by psychiatrists.
The investigators will remain in contact with those par-
ticipants who should be followed up to minimize pre-
mature discontinuation. The CRA will visit the
research site once a week and feedback the progress
and main problems to the principal investigator and
the executive management team. A monthly review of
the program progress, key problems and advice will be
reported to all researchers by the executive manage-
ment team. In addition, a group of experts assigned by
the executive management team will go to each site
twice a year to guide and confirm the protocol imple-
mentation and assess the reliability of clinical evalu-
ation. Inter-rater reliability for the primary outcome
measure (the 17-Item Hamilton Rating Scale for De-
pression, HRSD17) [39] is audited for each psychiatrist
who involved in clinical evaluation at each site annu-
ally. The executive management team calls for all prin-
cipal investigators and research coordinators once a
year face-to-face to discuss the difficulties and share
experience to ensure the protocol implementation and
study quality.
Study design
This is a multi-center, multi-stage and prospective study.
It includes 3 stages. (1) The first stage is a case–control
study, basing on the baseline information of 1200 MDD
patients (1200-MDD patients group) and 1200 health
controls (1200-Healthy controls group), aims to explore
the risk factors of developing MDD and then define the
subtypes of MDD. (2) The second stage is a diagnostic
test, basing on the baseline information, neuropsycho-
logical assessment and biological markers of 600 MDD
patients (600-MDD patients subgroup) and 300 health
controls (300-Healthy controls subgroup) from the first
stage, aims to indentify and replicate the potential indica-
tors to assist MDD diagnosis. (3) The third stage is a 96-
week longitudinal study, including 8-week acute period
treatment and 88-week stable period treatment of the
600-MDD patients subgroup. A total of 600 MDD pa-
tients from the first stage, who would receive one of 6
SSRIs within the range of does for 8 weeks (fluoxertine
hydrochloride 20-60 mg/day, paroxetine hydrochloride
20-60 mg/day, sertraline hydrochloride 50-200 mg/day,
citalopram 20-60 mg/day, escitalopram 10-20 mg/day, flu-
voxamine 50-300 mg/day) decided by their attending phy-
sicians, would enter into the second and third stage. The
600-MDD patients subgroup would receive clinical evalu-
ation at baseline, week 2, 4 and 8 and receive neuro-
psychological assessment and blood collection at baseline
and week 8 meanwhile. The aim of this phase is to identify
overall predictors of treatment effectiveness of SSRIs, basing
on the baseline information, clinical evaluation, neuropsycho-
logical assessment and biological markers of 600-MDD pa-
tients subgroup. The 600-MDD patients subgroup would
enter into the stable period treatment and be followed up
in the following 88 weeks after completing the above acute
period treatment. The treatment in the stable period
would be completely decided by their attending physicians
according to clinical practice. These patients would receive
clinical evaluation at week 24, 48 and 96 and receive
neuropsychological assessment and blood collection at
week 48 meanwhile. The aim of this phase is to explore
the predictors for MDD prognosis.
Participants
The participants are planned to enroll between December
2013 to December 2016. The goal is to recruit 1200 MDD
patients and 1200 healthy controls to complete baseline
evaluation and 300 out of 1200 healthy controls will
meanwhile receive neuropsychological assessment and
blood collection. The 600-MDD patients subgroup (600
out of 1200 MDD patients), who meet more strict criteria
and will receive one of 6 SSRIs for 8 weeks in acute period
as aforementioned, will be followed up for 96 weeks. The
details of inclusion and exclusion criteria for each group
are listed in Table 1.
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Enrollment, clinical treatment and follow-up
1. For 1200 MDD patients, the potential participants of
the outpatients and inpatients in each clinical sites
would be screened and enrolled by the investigators ac-
cording to the inclusion and exclusion criteria of 1200-
MDD patients firstly. To ensure representative and re-
flect the routine clinical practice, the treatment of eli-
gible MDD patients would be decided and adjusted by
their attending physicians. The 600-MDD patients sub-
group would receive the same type and dose of one of 6
SSRIs as aforementioned in the 8-week acute treatment
period. In this period, except additional treatments for
comorbid physical diseases or short-lasting benzodiaze-
pines for severe insomnia, other antipsychotic medica-
tions, other anti-depressant, mood stabilizer, systematic
psychotherapy and long-lasting benzodiazepines were
not allowed. The 600-MDD patients subgroup will re-
ceive clinical visits at 2nd, 4th, 8th, 24th, 48th and 96th
week in the following 96 weeks after baseline evaluation.
The primary treatment outcome evaluation index is the
change of the total score of HRSD17: treatment effective
defined as a ≥50 % decrease from the baseline total score
of HRSD17, clinical recovery defined as a ≥50 % decrease
from the baseline total score of HRSD17 and the total
score of HRSD17 < 7, no response defined as a <50 % de-
crease from the baseline total score of HRSD17. The sec-
ondary index includes the change of the total score of
Hamilton Anxiety Scale (HAMA), Global Impression of
Severity (CGI-S), number of MDD patients with serious
adverse events. Other 600 MDD patients will complete
this study after baseline evaluation.
2. For 1200 healthy controls, except for the researchers
involved in this study and the family members of en-
rolled MDD patients, those working in the clinical sites,
the friends of the patients, college students, or the resi-
dents near the clinical sites are all potential participants.
Those who are interested in this study will contact the
investigators and be enrolled according to the inclusion
and exclusion criteria of healthy controls. All healthy
controls will receive baseline evaluation and 300 out of
them will voluntarily receive neuropsychological assess-
ment and supply blood specimen.
See “Fig. 1 the research flowchart” for a detailed over-
view of the research procedure.
Data collection
Screening, demographic, clinical and cognitive function
data
At screening, the trained investigators gather participant
eligibility. The Chinese Version of MINI [40] was used
to confirm DSM-IV criteria for MDD [41], and assess
for psychiatric and substance abuse disorders and other
potential exclusion criteria. After enrollment, data of
demographic, medical history, family history of psychi-
atric disease, MDD course, treatment process, concur-
rent treatment, stress events, mood disorder episodes
and adverse events at baseline and/or follow-up point
would be collected using a set of self-designed question-
naire; other data, including life events in the past year,
adverse childhood experience, social support, coping
style, personality trait, anxiety symptom, depressive
symptom severity and improvement would be assessed
Table 1 The inclusion and exclusion criteria for MDD patients and healthy controls, respectively
Study group Inclusion criteria Exclusion criteria
1200-MDD
patients
(1) age between 18 and 55 years at the time of enrollment;
(2) diagnosis of MDD based on the Chinese Version of MINI
according to DSM-IV TR;
(3) first-episode or relapsed;
(4) having the ability of reading and writing to complete the
questionnaire and psychological assessment;
(5) providing written confirmation of informed consent.
(1) lifetime or current diagnosis of other psychotic disorder, alcohol/
substances dependence or cognitive impairment;
(2) severe somatic diseases, such as severe cardio-cerebral vascular
diseases, respiratory diseases, liver diseases, kidney diseases, or
malignant tumors;
(3) not signed the informed consent;




Besides those same as 1200-MDD patients’, more inclusion
criteria are as the follows:
(1) first-episode or relapsed more than1 time in the past
3 years and in acute episode period;
(2) total score of HRSD17≥ 14 when being screened;
(3) not taking anti-depressant regularly in the past 2 weeks or
should change anti-depressant according to the
psychiatrist’s advice.
Besides those same as 1200-MDD patients’, more exclusion criteria are
as the follows:
(1) resistant depression (not improved after taking 2 kinds of anti-
depressant with adequate dosage and duration;
(2) having history of epilepsy;
(3) taking MECT therapy in the past 3 months;
(4) pregnant or breast-feeding.
1200-Healthy
controls
(1) age between 18 and 55 years at the time of enrollment;
(2) providing written confirmation of informed consent prior
to engaging the study.
(1) lifetime or current diagnosis of any mental diseases;
(2) severe somatic diseases, such as severe cardio-cerebral vascular
diseases, respiratory diseases, liver diseases, kidney diseases, or
malignant tumors;
(3) not signed the informed consent;
(4) been engaging other studies.
Abbreviations: MDD major depressive disorder, MINI mini-international neuropsychiatric interview, DSM-IV TR diagnostic and statistical manual of mental disorders,
fourth edition text revision, HRSD17 the 17-item Hamilton rating scale for depression, MECT modified electric convulsive therapy
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and acquired using standardized Chinese version of scales,
respectively, including Life Events Scale, Childhood Trauma
Questionnaire, Social Support Questionnaire, Simplified
Coping Style Questionnaire and, Eysenck Personality
Questionnaire, Hamilton Anxiety Scale, HRSD17 and
Clinical Global impression Scale [39, 42].
A series of neuropsychological assessment [43] to re-
flect cognitive function will be completed at baseline for
600-MDD patients subgroup and 300-Healthy controls
subgroup, respectively, and also at 8th and 48th week
for 600-MDD patients subgroup, respectively. There are
5 domains and each is assessed by at least one test: at-
tention/vigilance assessed by Continuous Performance
Test-Identical Pairs, speed of information processing
assessed by Animal Verbal Fluency Scale, Color Trial
Test I and II and The Brief Assessment of Cognition in
Schizophrenia, visual learning assessed by Brief Visual
Memory Test-Revised, verbal learning assessed by Hop-
kins Verbal Learning Test-Revised and executive func-
tion assessed by Stroop Color Word Test. The trained
investigator would guide the participants completing the
tests according to standardized instructions. Except for
the test of Continuous Performance Test-Identical Pairs
completed using a standardized computerized touch
screen platform, other tests would be completed using
standardized scales guiding by the investigator.
The measure, participant, method, assessment time
and administrator of the data collection are listed in
Table 2.
Molecular data
Blood samples were collected by venepuncture at base-
line for 600-MDD patients subgroup and 300-Healthy
controls subgroup, respectively, and also at 8th and 48th
week for 600-MDD patients subgroup, respectively.
Plasma samples were collected in EDTA containing
tubes; within 1 h from blood sampling, they will be cen-
trifuged at 3000 rpm for 15 min. Afterward plasma sam-
ples were carefully transferred to new tubes and stored
at −80°Cuntil further analysis. Serum samples were col-
lected in anticoagulant-free tubes. After centrifugation,
serum will be drawn off and frozen at −80°Cuntil
needed. Avoid repeated freeze-thaw cycles. Assays will
be performed at the central laboratory (Peking Univer-
sity Sixth Hospital). Immune/inflammation and neuro-
trophic factor pathways have been implicated in the
pathogenesis of MDD. The activity of peripheral cyto-
kines correlates with inflammatory processes in the cen-
tral nervous system [32]. Immune and neurothrophic
biomarkers that maybe associated with MDD will be
measured in serum or plasma with commercially avail-
able kits following the manufacturer’s instructions.
Genomic DNA will be extracted from venous blood
using a commercially available QIAamp® DNA Blood
Mini Kit. Based on the HapMap database [44] and the
NCBI SNP database [45], we selected functional poly-
morphisms related to depression canidate genes with
minor allele frequencies (MAFs) >5 % according to the
HapMap database for CHB [44]. Functional polymor-
phisms will be determined using the F-SNP database
[46] which identifies polymorphisms with effects on pro-
tein coding, splicing regulation, transcription regulation,
and/or post translation. Genotyping will be conducted
using the Sequenom MassArray system (Sequenom
iPLEX assay) by following the manufacturer’s instruc-
tions. Approximately 15 ng of genomic DNA will be
used to genotype each sample. Locus-specific PCR and
detection primers will be designed using the MassArray
Assay Design 3.0 software (Sequenom). The DNA sam-
ples will be amplified by multiplex PCR reactions, and
the PCR products will then be used for locus-specific
single-base extension reaction. The resulting products
will be desalted and transferred to a 384-element Spec-
troCHIP array. Allele detection will be performed using
MALDI-TOF MS spectroscopy. The mass spectrograms
will be analyzed by the MassArray TYPER software
(Sequenom). To assess genotyping quality, 3.5 % of sam-











Clinical evaluation and biological indicators 
collection at 8th week (n=600)
Clinical evaluation at 24th week (n=600)
Clinical evaluation and biological indicators 
collection at 48th week (n=600)













MDD: major depressive disorder; SSRI: Selective Serotonin Reuptake Inhibitor 
Clinical evaluation at 2nd, 4th week (n=600)
Fig. 1 Research flowchart
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Sample size, power and effect size
The first goal of this study is to verify the role of herit-
ability and environment in the onset of MDD and iden-
tify a number of characteristics for defining the subtypes
of MDD. The study design for this part is a case–control
study. The sample size has been selected to detect small
effects for factors at odds ratio 1.5, if the proportion of
factors in control group more than10%, with a power of
0.85 and a two-tailed significance level at 0.05 and the
number of case equals control’s, a total of 1042 MDD
patients and 1042 healthy controls are intended to en-
roll. In view of 15 % data missing, a total of 1200 MDD
patients and 1200 healthy controls should be included.
The second goal of this study is to identify potential
indicators to assist MDD diagnosis. The study design for
this part is a diagnosis test study. The sample size has
been selected to detect small effects for indicators at
area under receiver operating characteristic curve more
than 0.6, with a power of 0.90 and a two-tailed signifi-
cance level at 0.05 and the number of case is twice of
control’s, a total of 260 MDD patients and 130 healthy
controls are intended to enroll. In view of 15 % data
missing, a total of 300 MDD patients and 150 healthy con-
trols should be included. To confirm the performance of
those indicators, another 300 MDD patients and 150
healthy controls should be included.
The third goal of this study is to identify factors which
are associated with treatment outcomes of SSRIs on
MDD. The study design for this part is a longitudinal-
based case–control study. The sample size has been se-
lected to detect small effects for factors at odds ratio 1.7,
if the proportion of factors in control group more than
30 %, with a power of 0.82 and a two-tailed significance
level at 0.05 and the number of case equal control’s (half
of MDD patients who receive one of 6 SSRIs in this
study would have treatment response at the end of week
8). A total of 520 MDD patients are intended to enroll.
In view of 13 % data missing, a total of 600 MDD pa-
tients should be included.
Data management
The data management center, basing on Java ezweb
using B/S structure, has developed a web-based data sys-
tem for data entering, checking and storage. After the
paper-based questionnaire completed and checked, the
site typist, with the typist’s ID and password, will input
the data into the web-based data system. The system,
using the regular express method to control the input
Table 2 Data Collection at Screening, Baseline and Follow-up Evaluation
Domain Measure Participant Method Assessment
time
Administrator
Informed consent Informed consent All participants Interview Screening Investigator
Eligibility Inclusion/Exclusion All participants Interview Screening Investigator
Psychiatric diagnoses MINI All participants Interview Screening Investigator
Demographic, medical history, family history
of psychiatric disease and MDD course
Self-designed
questionnaire
All participantsa Self-report Baseline Investigator
Life events in the past year, adverse




All participants Interview Baseline Investigator
Treatment process, concurrent treatment,






Self-report Every follow-up Investigator
Anxiety symptom HAMA 600-MDD patients
subgroup
Interview Every follow-up Investigator





Depressive symptom improvement CGIS 600-MDD patients
subgroup
Interview Every follow-up Investigator











Abbreviations: MINI Mini-International Neuropsychiatric Interview, LES Life Events Scale, CTQ Childhood Trauma Questionnaire, SSQ Social Support Questionnaire,
SCSQ Simplified Coping Style Questionnaire, EPQ Eysenck Personality Questionnaire, HAMA Hamilton Anxiety Scale, HRSD17 17-Item Hamilton Rating Scale for Depres-
sion, CGIS Clinical Global impression Scale, CPT-IP Continuous Performance Test-Identical Pairs, AVFSS Animal Verbal Fluency Scale, CTTIand II= Color Trial Test I and II, BACS
the Brief Assessment of Cognition in Schizophrenia, BVNT-R Brief Visual Memory Test-Revised, HVLT-R Hopkins Verbal Learning Test-Revised, SCWT Stroop Color Word Test
a Except “MDD course” for 1200 MDD patients only, other data of this domain would be collected for all participants
b For 300-Healthy controls subgroup, cognitive function data would only be collected at baseline
c Except for the data of CPT-IP collected using a standardized computerized touch screen platform, other data of this domain would be collected by the
trained investigator
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format for different data type, will do the basic format
and logic check when the typist inputting the data and
will give tips to the typist if the data out of the logic
range. After passing the system check, the typist will
clicked “submit” and then all the entered original data
will be transferred to database server and labeled ques-
tionable. The CRA, with the checker’s ID and password,
will then review the questionable data, mark and write
down their questions about the original data on the sys-
tem and inform the researcher and the site typist to an-
swer or modify the data, and then submit the reviewed
data. After the reviewed data submitted, the data man-
agement center will lock and store the data in the final
database using SQL Server 2008. The data system and
database are installed in a host server which is collocated
in an ISP server center and a special engineer is respon-
sible for daily maintenance. Only having the approval of
the executive management team, the engineer would ex-
port the database for the applicant. All data is de-
identified using a unique ID number. The source docu-
ments are retained by each site and will be archived
10 years beyond study completion.
Data preprocessing and statistical analysis
Systematically data cleaning and quantification will be
done before analysis. In the process of data preprocessing,
the most import step is to handle missing data. In this
study, missing data will be filled with average value of same
label samples. In view of distance calculation, techniques
of data normalization and standardization will be used.
The statistical analyses would be performed using
Stata 10.0 soft-ware. The details of analytic approach for
each study aim are as follows:
1. Verify the role of heritability and environment in
the onset of MDD and define the subtypes of MDD ac-
cording to the influence of heritability and environment
on its development.
According to classification hypothesis, significance test
for the classified characteristics of 1200-MDD patients
and1200-Healthy controls would be done. The con-
founding factors would be adjusted using regression
models. The interaction between heritability and envir-
onment on the onset of MDD would be evaluated using
logistic regression. Cluster analysis, K Nearest Neighbor
and K-means algorithms would be used to analyze the
demographic information, family history of psychiatric
diseases, life events in the past year, adverse childhood
experience, social support, coping style and personality
trait and to explore if MDD would be classify several
subtypes according to the influence of heritability and
environment on its development. For the sake of further
distinguish between this high dimensional data, fuzzy
clustering and spectral clustering would be employed in
this trail to distinguish subtypes of MDD.
2. Identify potential indicators to assist MDD diagnosis
basing on the baseline information, neuropsychological
assessment and biological markers.
The characteristics difference of 600-MDD patients
subgroup and 300-Healthy controls subgroup will be an-
alyzed. The correlation coefficient of each characteristic
would be calculated and redundant features would be re-
moved according to the experience of the clinical ex-
perts. Using logistic regression model to adjust the
confounding factors, the effect of the rest factor set on
outcome would be assessed and the main feature would
be selected according to the weight coefficient. The prin-
cipal component analysis and decision tree would be
used to realize dimensionality reduction if the factor set
is still large. To discriminate MDD patients from healthy
controls, various classifiers, including support vector
machines, decision tree, logistic regression and boosting,
will be employed to cater to the demand of current situ-
ation. Significance test would be done for the selected
factors and a characteristic will be considered an indica-
tor if the p-value is <0.05. Half of 600-MDD patients
subgroup and 300-Healthy controls subgroup would be
used to train the model, and the rest half would be used
to validate the model. The final indicators would be de-
termined according to the best one model.
3. Identify overall predictors of treatment effectiveness
on MDD after up to 8 weeks of SSRIs treatment and ex-
plore the predictors on MDD prognosis in the following
two years.
Comparing with the baseline, according to the rate of
decrease in HRSD17 at the end of 8-week, 600-MDD
participants would be divided into effective group (the rate
of decrease in HRSD17 ≥ 50 %) and ineffective group (the
rate of decrease in HRSD17 < 50 %). The characteristics
difference of the two groups will be analyzed. The correl-
ation coefficient of each characteristic would be calculated
and redundant features would be removed according to
the experience of the clinical experts. Using logistic re-
gression model to adjust the confounding factors, the ef-
fect of the rest factor set on outcome would be assessed
and the main feature would be selected according to the
weight coefficient. The principal component analysis
would be used to realize dimensionality reduction if the
factor set is still large. To predict treatment effectiveness,
various classifiers, including typical classifiers such as sup-
port vector machines, decision tree, logistic regression
and boosting and more powerful neural network, will be
employed to cater to the demand of current situation. Sig-
nificance test would be done for the selected factors and a
characteristic will be considered a predictor if the p-value
is <0.05. The final predictors would be determined accord-
ing to the best one model. The analysis plan for exploring
the predictors on MDD prognosis in the following two
years is similar to aforementioned.
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Ethical issues
This study had been approved by the Ethic Committee
of Peking University Sixth Hospital (approval NO. 2013-
29-1). Written informed consent was obtained from each
subject prior to undertaking any study-related proce-
dures. They will be informed that they can withdraw
from the study at any time without any negative conse-
quence. To conform to data protection and freedom of
information acts, all data will be stored securely and
anonymised wherever possible. No published material
will contain identifiable patient information. The study
procedure is being monitored and is being re-assessed
annually by the Ethic Committee of Peking University
Sixth Hospital.
Discussion
This study, a longitudinal, multi-stage and multi-center
study, aims to verify the role of heritability and environ-
ment in the onset of MDD, define the subtypes of MDD,
identify indicators to assist MDD diagnosis and assess
predictors of treatment effectiveness of SSRIs on MDD.
MDD may be divided into 3 types: heritability origin,
stress origin and others. Potential indicators for diagno-
sis and predictors for treatment effectiveness may in-
clude demographic characteristics, stress events, clinical
features, cognitive function, genotypes and peripheral
biomarkers. Participants are recruited from clinical and
academic sites to assemble a broadly inclusive and repre-
sentative population. Thus, the study results should be
widely generalization.
For different cause of MDD, the treatment response of
antidepressants on MDD is usually various. To improve
the treatment effectiveness, it is probably meaningful to
divide MDD into different subtypes basing on its origin.
To date, studies have typically examined one candidate
marker at a time for assisting MDD diagnosis or predict-
ing antidepressant response. By using standardized as-
sessments to assess multiple candidate markers in the
same study and same patients, this study provides en-
hanced statistical power to identify indicators to assist
MDD diagnosis and assess predictors for antidepressant
response. Promising preliminary empirical results
coupled with recent developments in statistical method-
ology suggest that paradigms could be developed to pro-
vide useful clinical decision support in personalized
treatment selection [47]. There will also be other strengths
to this study, including strict quality control procedure,
validated assessments by trained investigators, appropriate
statistical analysis plan.
This study will have some limitations. First, brain im-
aging data was not collected owing to financial limit.
Neuroimaging studies have demonstrated that brain im-
aging techniques could also assist to predict treatment
outcomes of MDD [30, 48, 49]. On the other side, brain
imaging techniques are quite complex and expensive at
present and so it may be not suitable as a predictor for
treatment response, especially in developing countries
and regions. In this light, the predictors for treatment
response on MDD studied in this study would be easily
generalized. Second, the treatment for MDD patients is
decided and adjusted by their attending physicians and
they will be selected into this study if they meet the in-
clusion criteria. To some extent, the MDD subjects
probably mirror clinical practice in a representative
spectrum of MDD patients.
Conclusion
MDD patients usually display a wide variation in clinical
symptoms and sign, while the diagnosis of MDD is rela-
tively subjective. A about half of MDD patients fail to
respond adequately to the first antidepressant. The de-
velopment of neurobiology and statistical methodology
make it sense to combine a set of possible factors for
assisting the diagnosis and improving treatment effect-
iveness of MDD. The results of this study should provide
strong and suitable evidence for enhancing the accuracy
of MDD diagnosis and promoting personalized treat-
ment for MDD in clinical practice.
Trial status
The recruitment of participants started in December
2013 and will stop at December 2016.
Role of the funding source
This project is funded by the National Key Basic Research
Program of China (No.2013CB531305). The study proto-
col has undergone peer-review by the funding body.
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